NCT04971395View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Healthy Participants
Interventions
DRUG

Placebo

Single dose of 2 or 4 mg/kg

DRUG

XTMAB-16 2 mg/kg

Single dose of 2 mg/kg

DRUG

XTMAB-16 4mg/kg

Single dose of 4 mg/kg

Trial Locations (1)

21225

MedStar Harbor Hospital, Baltimore

All Listed Sponsors
lead

Xentria, Inc.

INDUSTRY